Aarti PharmalabsBOM:543748 -2.69%58 Net Margin % is 10.49% as of Mar. 2026, which is 2% above its 10-year median of 10.26. GuruFocus rates BOM:543748 with a GF Score™ of 58/100 and a GF Value™ of ₹636.88 (Fairly Valued). The stock has 3 warning signs investors should review. Among 956 Drug Manufacturers companies, Aarti Pharmalabs ranks better than 65.38% on this metric.
The historical rank and industry rank for Aarti Pharmalabs's Net Margin % or its related term are showing as below:
BOM:543748'
s Net Margin % Range Over the Past 10 Years
Min: 9.6 Med: 10.26 Max: 12.88
Current: 10.25
BOM:543748's Net Margin % is ranked better than 65.38% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs BOM:543748: 10.25
Aarti Pharmalabs (BOM:543748) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Aarti Pharmalabs Net Margin % Related Terms
Aarti Pharmalabs Net Margin % Historical Data
* Premium members only.
The historical data trend for Aarti Pharmalabs's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Pharmalabs's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aarti Pharmalabs Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aarti Pharmalabs's Net Margin % distribution charts can be found below:
* The bar in red indicates where Aarti Pharmalabs's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aarti Pharmalabs (BOM:543748) has a Net Margin % of 10.49% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Aarti Pharmalabs and its competitors. This is near median its historical median of 10.26. Over the past decade, Aarti Pharmalabs' Net Margin % has ranged from 9.60 to 12.88. According to the industry distribution chart, Aarti Pharmalabs ranks #331 out of 956 companies in the Drug Manufacturers industry, placing it in the top 34.6%.
Is Aarti Pharmalabs' Net Margin % too high?
Aarti Pharmalabs' current Net Margin % of 10.49% is near median its 10-year median of 10.26. Over the past 10 years, this metric has ranged from a low of 9.60 to a high of 12.88. The Drug Manufacturers industry median Net Margin % is 5.56. Aarti Pharmalabs' value of 10.49% is 88.7% above this industry median. Based on the distribution chart, Aarti Pharmalabs ranks #331 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aarti Pharmalabs has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aarti Pharmalabs' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Aarti Pharmalabs ranks #331 out of 956 companies for Net Margin %. This puts Aarti Pharmalabs in the upper half of its industry. The industry median Net Margin % is 5.56. Aarti Pharmalabs' value of 10.49% is 88.7% above this benchmark. Historically, Aarti Pharmalabs' own Net Margin % has ranged from 9.60 to 12.88 over the past decade. While the company's 10-year median is 10.26 vs. the industry median of 5.56, Aarti Pharmalabs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aarti Pharmalabs's current Net Margin % of 10.49% is 88.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Aarti Pharmalabs and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aarti Pharmalabs's current Net Margin % is 10.49%, which is near median its own 10-year median of 10.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Pharmalabs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Pharmalabs (BOM:543748) is currently considered Fairly Valued. The stock's GF Value™ is ₹636.88, compared to a current price of ₹691.50 — trading 8.6% above its estimated fair value. The current Net Margin % is 10.49%, which is near median its 10-year median of 10.26 and 88.7% above the Drug Manufacturers industry median of 5.56. Aarti Pharmalabs' overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Aarti Pharmalabs (BOM:543748), the current Net Margin % is 10.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aarti Pharmalabs (BOM:543748) Overvalued in 2026?
Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued.
The current stock price of ₹691.50 is trading 8.6% above its estimated GF Value™ of ₹636.88.
GuruFocus considers Aarti Pharmalabs to be Fairly Valued.
Key valuation signals for BOM:543748:
Net Margin %: 10.49% (near median its 10-year median of 10.26)
GF Value™: ₹636.88 vs. price of ₹691.50 (8.6% above fair value)
Industry Position: 88.7% above the Drug Manufacturers median (#331 of 956)
No single metric tells the full story. See the BOM:543748 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
58GF Score
Get the complete analysis for BOM:543748
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543748 has been successfully added to your 
